BAYSTATE MEDICAL CENTER
- Type
- Teaching hospital
- Where
- SPRINGFIELD, MA
- Medicare CCN
- 220077
- Received
- $977,171 in 201 records, 2019 ($68,875 general, $908,296 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Baystate Medical Center, Inc. Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Patent assignee: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Trademark owner: Baystate Medical Center, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 32 | $68,875 |
| 2019 | Research payment | 169 | $908,296 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 169 | $908,296 |
| Gift | 13 | $31,255 |
| Grant | 4 | $22,382 |
| Space rental or facility fees (teaching hospital only) | 8 | $8,807 |
| Education | 5 | $5,145 |
| Charitable Contribution | 2 | $1,284 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Medartis Inc. | $10,851 | Gift (4 payments) | In-kind items and services | APTUS Device, ORTHO | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $8,436 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $730 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $534 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Masimo Corporation | $284 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Edwards Lifesciences Corporation | $172 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $142 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $35 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $12 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-12-24 | Amgen Inc. | $19,425 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS-CV | 2019 |
| 2019-12-20 | Genentech, Inc. | $14,571 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,764 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-12-16 | Medtronic Vascular, Inc. | $473 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-16 | Medtronic Vascular, Inc. | $473 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-11 | Medtronic Vascular, Inc. | $1,750 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-11 | Medtronic Vascular, Inc. | $1,750 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-11 | Medtronic Vascular, Inc. | $150 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-11 | Medtronic Vascular, Inc. | $150 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-12-05 | Roche Diagnostics Corporation | $9,560 | Gift | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | 2019 | |
| 2019-12-03 | ViiV Healthcare Company | $1,000 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-11-27 | Roche Diagnostics Corporation | $16 | Gift | In-kind items and services | CD Middleware Solutions Device, Centralized Diagnostics | 2019 | |
| 2019-11-22 | ViiV Healthcare Company | $408 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-11-18 | GENZYME CORPORATION | $1,105 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry LSD Data Registry | 2019 |
| 2019-11-18 | GENZYME CORPORATION | $650 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe LSD Data Registry | 2019 |
| 2019-11-18 | GENZYME CORPORATION | $292 | Research payment | Cash or cash equivalent | MPS I-DISEASE Drug | MPS-I LSD Data Registry | 2019 |
| 2019-11-15 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-14 | Daiichi Sankyo Inc. | $8,450 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $3,250 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $2,500 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $1,300 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $689 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-14 | Daiichi Sankyo Inc. | $650 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2019 |
| 2019-11-13 | Medtronic Vascular, Inc. | $10,717 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-11-13 | Medtronic Vascular, Inc. | $10,717 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-11-12 | Genentech, Inc. | $17,866 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-11-06 | JAZZ PHARMACEUTICALS INC. | $121 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-11-01 | Abbott Laboratories | $3,200 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-10-30 | Gilead Sciences, Inc. | $1,150 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-10-28 | Gilead Sciences, Inc. | $750 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-10-24 | ViiV Healthcare Company | $273 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-10-22 | Olympus America Inc. | $3,801 | Education | In-kind items and services | 4-K Device, Surgical Endoscopy Products | 2019 | |
| 2019-10-21 | Genentech, Inc. | $10,962 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-10-16 | TESARO, Inc. | $504 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-10-15 | Medtronic Vascular, Inc. | $2,297 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-15 | Medtronic Vascular, Inc. | $2,297 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-15 | Medtronic Vascular, Inc. | $1,490 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-10-15 | Medtronic Vascular, Inc. | $1,490 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-10-10 | Genentech, Inc. | $34,841 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $43 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $31 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $25 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | Medtronic Vascular, Inc. | $25 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-07 | Medtronic Vascular, Inc. | $25 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $21 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $18 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $10 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $10 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $10 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $6 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $5 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-07 | JAZZ PHARMACEUTICALS INC. | $1 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-10-04 | Genentech, Inc. | $10,647 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $650 | Research payment | Cash or cash equivalent | MPS I-DISEASE Drug | MPS-I LSD Data Registry | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $650 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry LSD Data Registry | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $650 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe LSD Data Registry | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $133 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe LSD Data Registry | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $133 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry LSD Data Registry | 2019 |
| 2019-10-01 | GENZYME CORPORATION | $133 | Research payment | Cash or cash equivalent | MPS I-DISEASE Drug | MPS-I LSD Data Registry | 2019 |
| 2019-09-27 | Bolton Medical Inc | $1,185 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-27 | Bolton Medical Inc | $1,185 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-25 | Cytyc Corporation | $20,605 | Research payment | Cash or cash equivalent | Fetal Fiberectin Device, Diagnostics | fFN Quant Study | 2019 |
| 2019-09-19 | E.R. Squibb & Sons, L.L.C. | $11,750 | Research payment | Cash or cash equivalent | SAD POC in Severe Sepsis | 2019 | |
| 2019-09-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,000 | Research payment | Cash or cash equivalent | COPD pragmatic randomised clinical trial | 2019 | |
| 2019-09-19 | Medtronic Vascular, Inc. | $3,735 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-09-19 | Medtronic Vascular, Inc. | $3,735 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-09-18 | Gilead Sciences, Inc. | $1,652 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-09-16 | GENZYME CORPORATION | $1,325 | Research payment | Cash or cash equivalent | LUMIZYME Drug, RARE DISEASE GENETICS | Pompe Disease Registry | 2019 |
| 2019-09-16 | Bolton Medical Inc | $1,185 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $1,185 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | GENZYME CORPORATION | $1,050 | Research payment | Cash or cash equivalent | FABRAZYME Drug, RARE DISEASE GENETICS | Fabry Disease Registry | 2019 |
| 2019-09-16 | Bolton Medical Inc | $1,000 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $1,000 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $1,000 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-09-16 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-08-23 | Medtronic Vascular, Inc. | $6,822 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-08-23 | Medtronic Vascular, Inc. | $6,822 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-08-23 | Endologix LLC | $2,806 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2019 | |
| 2019-08-23 | Medtronic Vascular, Inc. | $2,619 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-08-23 | Medtronic Vascular, Inc. | $2,619 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-08-23 | Endologix LLC | $1,740 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2019 | |
| 2019-08-21 | Gilead Sciences, Inc. | $762 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-08-13 | Genentech, Inc. | $35,335 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-08-12 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-08-08 | ABIOMED | $2,000 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | DTU | 2019 |
| 2019-08-06 | Chiesi USA, Inc. | $1,096 | Research payment | Cash or cash equivalent | CCD-5633AA1-02 | 2019 | |
| 2019-07-25 | Arrow International, Inc. | $920 | Gift | Cash or cash equivalent | CATHETER - ARROW Device, Vascular | 2019 | |
| 2019-07-23 | ViiV Healthcare Company | $8,552 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-07-22 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-22 | SEAGEN INC. | $11,250 | Research payment | Cash or cash equivalent | A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Met | 2019 | |
| 2019-07-18 | TESARO, Inc. | $20,300 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-17 | Amicus Therapeutics, Inc. | $7,825 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2019 | |
| 2019-07-17 | Gilead Sciences, Inc. | $3,894 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-07-16 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-07-15 | GENZYME CORPORATION | $267 | Research payment | Cash or cash equivalent | FABRAZYME Drug, RARE DISEASE GENETICS | Fabry Disease Registry | 2019 |
| 2019-07-15 | GENZYME CORPORATION | $267 | Research payment | Cash or cash equivalent | ALDURAZYME Drug, RARE DISEASE GENETICS | MPS I Disease Registry | 2019 |
| 2019-07-15 | GENZYME CORPORATION | $266 | Research payment | Cash or cash equivalent | LUMIZYME Drug, RARE DISEASE GENETICS | Pompe Disease Registry | 2019 |
| 2019-07-11 | Genentech, Inc. | $32,548 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-07-11 | HOLOGIC INC | $18,070 | Research payment | Cash or cash equivalent | Fetal Fiberectin Device, Diagnostics | fFN Quant Study | 2019 |
| 2019-07-11 | ABIOMED | $1,750 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | DTU | 2019 |
| 2019-07-03 | PFIZER INC. | $999 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2019 | |
| 2019-07-02 | Abbott Laboratories | $4,325 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-07-02 | GENZYME CORPORATION | $1,083 | Research payment | Cash or cash equivalent | LUMIZYME Drug, RARE DISEASE GENETICS | Pompe Disease Registry | 2019 |
| 2019-07-02 | GENZYME CORPORATION | $1,083 | Research payment | Cash or cash equivalent | ALDURAZYME Drug, RARE DISEASE GENETICS | MPS I Disease Registry | 2019 |
| 2019-07-02 | GENZYME CORPORATION | $1,083 | Research payment | Cash or cash equivalent | FABRAZYME Drug, RARE DISEASE GENETICS | Fabry Disease Registry | 2019 |
| 2019-06-28 | Bolton Medical Inc | $1,185 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Endovascular | RelayPro-A IP-0015-16 | 2019 |
| 2019-06-20 | TREACE MEDICAL CONCEPTS, INC. | $1,059 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lapiplasty System Device, Y | 2019 | |
| 2019-06-18 | Amicus Therapeutics, Inc. | $13,000 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2019 | |
| 2019-06-08 | Masimo Corporation | $597 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2019 | |
| 2019-06-03 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-30 | Medtronic Vascular, Inc. | $17,091 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-05-30 | Medtronic Vascular, Inc. | $17,091 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2019 | |
| 2019-05-30 | Medtronic Vascular, Inc. | $10,438 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-05-30 | Medtronic Vascular, Inc. | $10,438 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-05-29 | Celgene Corporation | $7,185 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MM | 2019 |
| 2019-05-17 | Theratechnologies Inc. | $999 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-15 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-13 | Genentech, Inc. | $80,165 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-05-13 | GENZYME CORPORATION | $5,700 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry Disease Registry | 2019 |
| 2019-05-13 | GENZYME CORPORATION | $675 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe Disease Registry | 2019 |
| 2019-05-13 | GENZYME CORPORATION | $100 | Research payment | Cash or cash equivalent | MPS I-DISEASE Drug | MPS I Disease Registry | 2019 |
| 2019-04-26 | Helena Laboratories Corporation | $263 | Gift | In-kind items and services | 2019 | ||
| 2019-04-24 | ViiV Healthcare Company | $943 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-04-18 | ViiV Healthcare Company | $3,538 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-04-18 | Chiesi USA, Inc. | $2,136 | Research payment | Cash or cash equivalent | CCD-5633AA1-02 | 2019 | |
| 2019-04-18 | TESARO, Inc. | $980 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-17 | Gilead Sciences, Inc. | $5,814 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-04-16 | Chiesi USA, Inc. | $6 | Research payment | In-kind items and services | CCD-5633AA1-02 | 2019 | |
| 2019-04-12 | Endologix LLC | $3,386 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2019 | |
| 2019-04-12 | Endologix LLC | $2,806 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2019 | |
| 2019-04-12 | Endologix LLC | $580 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2019 | |
| 2019-04-05 | Abbott Laboratories | $306 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Evaluation of XIENCE PRIME Everolimus Eluting Stent System (EECSS) or XIENCE V EECSS or XIENCE Xpedition EECSS or XIENCE | 2019 |
| 2019-04-05 | JAZZ PHARMACEUTICALS INC. | $121 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-04-05 | JAZZ PHARMACEUTICALS INC. | $25 | Research payment | Cash or cash equivalent | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2019 | |
| 2019-04-02 | Genentech, Inc. | $5,062 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-04-01 | Cytyc Corporation | $10,420 | Research payment | Cash or cash equivalent | Fetal Fiberectin Device, Diagnostics | fFN Quant Study | 2019 |
| 2019-04-01 | Gilead Sciences, Inc. | $3,756 | Research payment | Cash or cash equivalent | Odefsey Drug, HIV | A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Te | 2019 |
| 2019-04-01 | Gilead Sciences, Inc. | $2,414 | Research payment | Cash or cash equivalent | Genvoya Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/T | 2019 |
| 2019-04-01 | Abbott Laboratories | $1,425 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-04-01 | Gilead Sciences, Inc. | $1,384 | Research payment | Cash or cash equivalent | Odefsey Drug, HIV | A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenof | 2019 |
| 2019-04-01 | Abbott Laboratories | $100 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-03-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,000 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Pulmonary Rehabilitation and Nintedanib in IPF | 2019 |
| 2019-03-23 | Olympus America Inc. | $38 | Gift | In-kind items and services | Olympus Capital Accessories Device, Surgical Endoscopy Products | 2019 | |
| 2019-03-23 | Olympus America Inc. | $2 | Gift | In-kind items and services | Device, Surgical Endoscopy Products | 2019 | |
| 2019-03-21 | Olympus America Inc. | $246 | Gift | In-kind items and services | Device, Surgical Endoscopy Products | 2019 | |
| 2019-03-14 | Advanced Respiratory, Inc | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | The MetaNeb System Device, Airway Clearance Device | 2019 | |
| 2019-03-12 | Medtronic Vascular, Inc. | $1,432 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-03-12 | Medtronic Vascular, Inc. | $1,432 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-03-11 | GENZYME CORPORATION | $10,075 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry Disease Registry | 2019 |
| 2019-03-11 | GENZYME CORPORATION | $2,100 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe Disease Registry | 2019 |
| 2019-03-11 | GENZYME CORPORATION | $700 | Research payment | Cash or cash equivalent | MPS I-DISEASE Drug | MPS IDISEASE (612690303) | 2019 |
| 2019-03-01 | Ferring International Pharmascience Center US | $2,375 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-03-01 | Medline Industries LP | $750 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-02-22 | E.R. Squibb & Sons, L.L.C. | $999 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2019 | |
| 2019-02-21 | AstraZeneca Pharmaceuticals LP | $6,589 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-02-20 | Gilead Sciences, Inc. | $1,780 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-02-20 | Linvatec Corporation | $1,383 | Grant | In-kind items and services | FLUID MANAGEMENT/PUMPS Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-02-19 | Medtronic Vascular, Inc. | $2,964 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-02-12 | Genentech, Inc. | $73,720 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-02-10 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-02-10 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Drug, Respiratory | 2019 | |
| 2019-02-06 | Ferring International Pharmascience Center US | $5,845 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-02-06 | Ferring International Pharmascience Center US | $1,882 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-02-06 | Ferring International Pharmascience Center US | $1,000 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-02-06 | Ferring International Pharmascience Center US | $902 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-02-05 | E.R. Squibb & Sons, L.L.C. | $14,150 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Multiple Myeloma 3L Combo nivo - elo | 2019 |
| 2019-02-05 | Baxter Healthcare | $2,560 | Research payment | Cash or cash equivalent | TISSEEL Biological, Surgical Care | Efficacy and Safety of FS VH S-D 500 S-apr as an Adjunct to Sutured Dural Repair in Cranial Surgery -3599001- | 2019 |
| 2019-02-01 | Ferring International Pharmascience Center US | $4,814 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-02-01 | Ferring International Pharmascience Center US | $500 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-29 | Allergan, Inc. | $845 | Research payment | Cash or cash equivalent | VIIBRYD Drug, NEUROSCIENCE | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF VILAZODONE IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER | 2019 |
| 2019-01-28 | Abbott Laboratories | $3,125 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2019 |
| 2019-01-28 | Gilead Sciences, Inc. | $890 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-01-23 | Leadiant Biosciences, Inc. | $14,679 | Research payment | Cash or cash equivalent | STP206 Biological, Neonatal gastroenterology | A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Prematu | 2019 |
| 2019-01-22 | ViiV Healthcare Company | $2,565 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2019 |
| 2019-01-18 | Ferring International Pharmascience Center US | $3,185 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-18 | Ferring International Pharmascience Center US | $2,800 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-18 | Ferring International Pharmascience Center US | $2,800 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-18 | Ferring International Pharmascience Center US | $625 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-17 | BSN Medical Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-01-17 | Allergan, Inc. | $905 | Research payment | Cash or cash equivalent | VIIBRYD Drug, NEUROSCIENCE | A MULTICENTER, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED PARALLEL-GROUP EVALUATION OF THE SAFETY AND EFFICACY OF VILAZ | 2019 |
| 2019-01-16 | FUJIFILM SonoSite, Inc. | $289 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2019 | |
| 2019-01-14 | Medtronic Vascular, Inc. | $200 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-01-10 | Medtronic Vascular, Inc. | $24,622 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-01-10 | Medtronic Vascular, Inc. | $24,622 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2019 |
| 2019-01-09 | Ferring International Pharmascience Center US | $1,939 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 | |
| 2019-01-09 | Ferring International Pharmascience Center US | $1,500 | Research payment | Cash or cash equivalent | A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety | 2019 |
The latest 200 records of 201.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, MA, county Hampden County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Springfield, MA | County Hampden County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 154,749 | 462,815 | 7,044,056 |
| Population, 2020 census P1 | 155,929 | 465,825 | 7,029,917 |
| Median age B01002 | 33.7 | 40.0 | 40.0 |
| Under 18 B01001 | 24.2% | 20.9% | 19.4% |
| 65 and over B01001 | 13.2% | 18.3% | 17.9% |
| Households B11001 | 57,772 | 184,471 | 2,785,042 |
| Foreign born B05002 | 10.5% | 9.4% | 18.0% |
| Median household income B19013 | $52,656 | $71,306 | $103,960 |
| Median family income B19113 | $66,045 | $91,397 | $131,675 |
| Per capita income B19301 | $27,337 | $38,219 | $57,897 |
| Poverty rate B17001 | 25.8% | 16.3% | 10.0% |
| Unemployment rate B23025 | 8.7% | 6.0% | 5.2% |
| Civilian labor force B23025 | 69,390 | 226,771 | 3,911,446 |
| Mean commute (minutes) B08013 | 20.2 | 22.7 | 29.1 |
| Bachelor's degree or higher B15003 | 20.5% | 29.3% | 47.3% |
| Housing units B25001 | 62,217 | 197,591 | 3,030,406 |
| Owner-occupied B25003 | 49.6% | 62.2% | 62.5% |
| Renters B25003 | 50.4% | 37.8% | 37.5% |
| Median home value B25077 | $245,000 | $298,800 | $562,100 |
| Median gross rent B25064 | $1,144 | $1,136 | $1,762 |
| White, not Hispanic B03002 | 27.8% | 59.3% | 66.6% |
| Black B03002 | 17.5% | 7.6% | 6.4% |
| Hispanic or Latino B03002 | 48.6% | 27.0% | 13.3% |
| Asian B03002 | 2.7% | 2.5% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, MA.
Comments